patents.google.com

MX2017014743A - Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina. - Google Patents

  • ️Fri Jan 26 2018
Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina.

Info

Publication number
MX2017014743A
MX2017014743A MX2017014743A MX2017014743A MX2017014743A MX 2017014743 A MX2017014743 A MX 2017014743A MX 2017014743 A MX2017014743 A MX 2017014743A MX 2017014743 A MX2017014743 A MX 2017014743A MX 2017014743 A MX2017014743 A MX 2017014743A Authority
MX
Mexico
Prior art keywords
pancreatin
manufacture
microbial content
processes
reducing
Prior art date
2015-05-19
Application number
MX2017014743A
Other languages
English (en)
Other versions
MX380367B (es
Inventor
Wang Yan
S Manning Kenethe
Nielsen Dustin
RUF Ryan
Crowley Colin
RESTIVO Jon
Spangenberg Dana
Anhalt Karla
ROMICH Mark
Akula Anisha
Fritz Carmen
Original Assignee
Scient Protein Laboratories Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2015-05-19
Filing date
2016-05-19
Publication date
2018-01-26
2016-05-19 Application filed by Scient Protein Laboratories Llc filed Critical Scient Protein Laboratories Llc
2018-01-26 Publication of MX2017014743A publication Critical patent/MX2017014743A/es
2025-03-12 Publication of MX380367B publication Critical patent/MX380367B/es

Links

  • 238000000034 method Methods 0.000 title abstract 5
  • 108010019160 Pancreatin Proteins 0.000 title abstract 3
  • 229940055695 pancreatin Drugs 0.000 title abstract 3
  • 230000003612 virological effect Effects 0.000 title abstract 3
  • 238000004519 manufacturing process Methods 0.000 title abstract 2
  • 230000000813 microbial effect Effects 0.000 title abstract 2
  • 230000000415 inactivating effect Effects 0.000 title 1
  • KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 abstract 4
  • 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
  • 230000001580 bacterial effect Effects 0.000 abstract 1
  • 230000000762 glandular Effects 0.000 abstract 1
  • 230000002779 inactivation Effects 0.000 abstract 1
  • 210000000496 pancreas Anatomy 0.000 abstract 1

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14361—Methods of inactivation or attenuation
    • C12N2750/14363—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus
    • C12N2770/32261—Methods of inactivation or attenuation
    • C12N2770/32263—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe un método para la reducción inactivación del contenido viral y microbiano en la fabricación del ingrediente farmacéutico activo pancreatina. El método incluye tratar tejido derivado de animal con ácido peracético para reducir la actividad viral y la carga bacteriana antes del procesamiento. En particular, el método incluye tratar páncreas porcino con ácido peracético antes de extraer un ingrediente farmacéutico activo pancreatina del tejido glandular tratado.

MX2017014743A 2015-05-19 2016-05-19 Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina. MX380367B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163779P 2015-05-19 2015-05-19
PCT/US2016/033329 WO2016187455A1 (en) 2015-05-19 2016-05-19 Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin
US15/159,345 US10093916B2 (en) 2015-05-19 2016-05-19 Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin

Publications (2)

Publication Number Publication Date
MX2017014743A true MX2017014743A (es) 2018-01-26
MX380367B MX380367B (es) 2025-03-12

Family

ID=57320830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014743A MX380367B (es) 2015-05-19 2016-05-19 Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina.

Country Status (7)

Country Link
US (2) US10093916B2 (es)
EP (1) EP3298139B1 (es)
CN (2) CN107849552B (es)
CY (1) CY1124679T1 (es)
MX (1) MX380367B (es)
PL (1) PL3298139T3 (es)
WO (1) WO2016187455A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093916B2 (en) * 2015-05-19 2018-10-09 Scientific Protein Laboratories, Llc Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin
CN108795920B (zh) * 2018-06-22 2022-04-08 苏州良辰生物医药科技有限公司 一种胰酶的制备方法
CN109810968B (zh) * 2019-03-13 2021-03-02 淮安麦德森制药有限公司 胰酶的制备方法
CN112708611A (zh) * 2021-01-19 2021-04-27 四川菲德力制药有限公司 一种胰酶制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956483A (en) 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
US4986963A (en) 1989-01-24 1991-01-22 Corcoran Richard A Method of disinfecting contact lenses with peracetic acid
US20020192731A1 (en) * 2001-04-12 2002-12-19 H. Shih Jason C. Method and composition for sterilizing surgical instruments
US6749851B2 (en) 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
US8168233B2 (en) * 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
UA93384C2 (ru) * 2005-07-29 2011-02-10 Солвей Фармасьютикалс Гмбх Способ получения стерилизированного порошкообразного панкреатина
CN101821389B (zh) * 2007-11-15 2012-05-30 索尔瓦药物有限公司 用于分离和测定胰酶样品中病毒载量的新方法
US20090130063A1 (en) 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2165717A1 (de) * 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
ATE541591T1 (de) 2008-11-03 2012-02-15 Nordmark Arzneimittel Gmbh & Co Kg Verfahren zur verringerung der viralen und mikrobiellen belastung von pankreatin
SG178090A1 (en) * 2009-07-21 2012-03-29 Transgene Sa Enzymatic composition for the digestion of chicken embryos
US9511125B2 (en) * 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
KR102173873B1 (ko) 2009-11-12 2020-11-04 브이셀 세라퓨틱스 인코포레이티드 포자를 닮은 세포들의 계군 및 그 용도
EP2547765A4 (en) 2010-03-19 2013-09-04 Aptalis Pharma Canada Inc BETA-PROPIOLACTONE FOR INACTIVATING VIRUSES IN PANCREATIC PHARMACEUTICAL ENZYMATIC PREPARATIONS
US10093916B2 (en) * 2015-05-19 2018-10-09 Scientific Protein Laboratories, Llc Method for reducing or inactivating viral and microbial content in the processes for the manufacture of pancreatin

Also Published As

Publication number Publication date
CN107849552B (zh) 2021-11-02
US20180362958A1 (en) 2018-12-20
US11952603B2 (en) 2024-04-09
WO2016187455A1 (en) 2016-11-24
PL3298139T3 (pl) 2022-01-31
CY1124679T1 (el) 2022-07-22
MX380367B (es) 2025-03-12
US10093916B2 (en) 2018-10-09
CN113750224B (zh) 2024-04-30
CN113750224A (zh) 2021-12-07
EP3298139A4 (en) 2019-02-06
BR112017024920A2 (pt) 2018-07-31
US20170037392A1 (en) 2017-02-09
EP3298139A1 (en) 2018-03-28
EP3298139B1 (en) 2021-09-15
CN107849552A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
BR112021011289A2 (pt) 2022-04-26 Composição farmacêutica para prevenção ou tratamento de câncer compreendendo weissella cibaria wikim28 como ingrediente ativo
MX2023007212A (es) 2023-06-29 Formulaciones de pulverizacion de epinefrina.
MX2017013983A (es) 2018-03-15 Uso de agentes activos durante tratamientos quimicos.
MX2020000713A (es) 2020-08-31 Metodos de aferesis y sus usos.
EP3530124A4 (en) 2020-10-21 DIET CONTAINING A SUBTILUS BACILIUS STRAIN, BACILIUS PUMILUS STRAIN AND BACILIUS LICHENFORMIS STRAIN AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING ACUTE HEPATOPANCREATIC NECROSIS DISEASE OR BLANCHANCHESIS SYNDROME
MX2017014743A (es) 2018-01-26 Metodo para reducir o inactivar contenido viral o microbiano en los procesos para la fabricacion de pancreatina.
BR112017022768A2 (pt) 2018-07-31 desinfecção de tecido com ondas de choque de pressão acústica
NZ728429A (en) 2024-07-05 Acinetobacter lysins
PH12017501300A1 (en) 2018-02-05 Novel iodophor composition and methods of use
PH12020550942A1 (en) 2021-05-10 Antimicrobial peptides and methods of using same
AR101811A1 (es) 2017-01-11 Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular
EA201791051A1 (ru) 2018-01-31 Способ лечения, профилактики или снижения риска возникновения кожной инфекции
MX2018001777A (es) 2018-05-16 Sistema conservante.
BR112017028590A2 (pt) 2018-08-28 novo lipolantipeptídeo bicíclico, preparação e uso como agente antimicrobiano
EA201390487A1 (ru) 2013-08-30 Антимикробный белок
MX2019002405A (es) 2019-06-20 Desactivacion de patogenos en medios biologicos.
EA201891922A1 (ru) 2019-02-28 Лекарственное средство для лечения инфекций на фоне диабетической стопы
BR112021011293A2 (pt) 2021-11-23 Composição farmacêutica para prevenção ou tratamento de câncer compreendendo lactobacillus sakei wikim30 como ingrediente ativo
EA201992210A1 (ru) 2020-05-15 Предотвращение и/или лечение воспалительного заболевания кожи
MX2021003749A (es) 2021-05-27 Composicion farmaceutica para prevenir o tratar la enfermedad de fabry, que contiene inhibidor de la proteina trombospondina (tsp1) como ingrediente activo.
UY36273A (es) 2016-04-01 Composicion para el tratamiento de neuropatías y del dolor neuropático
WO2019126695A3 (en) 2020-03-26 Methods and pharmaceutical compositions for treating candida auris in blood
EA201992234A1 (ru) 2020-02-05 Средство для профилактики миопии, лечения миопии и/или предотвращения прогрессирования миопии, включающее тиотропий в качестве активного ингредиента
BR112018005268A2 (pt) 2018-10-09 nanopartículas não vesiculares altamente estáveis e aplicação das mesmas no tratamento de infecção microbiana”
MX2017011040A (es) 2017-11-10 Agente para el tratamiento de infeccion respiratoria.